Prostate drug boosts PFS in metastatic disease

'This is very different from chemotherapy,' study author says

In men with metastatic castration-sensitive prostate cancer, adding apalutamide to conventional androgen-deprivation therapy can produce a 52% increase in the rate of radiographic progression-free survival, researchers report.